Company intelligence / Profile preview
RinuaGene Biotechnology
Suzhou/Suzhou Industrial Park, Jiangsu Sheng/Jiangsu Province, Chinarinuagene.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
RinuaGene’s lead candidate RG002—an mRNA-LNP therapeutic vaccine targeting high-risk HPV—received FDA IND approval in October 2023 for CIN II/III. It represents the world’s first approved mRNA-LNP therapeutic vaccine IND for this indication. Preclinical data show strong immunogenicity and tumor regression in animal models. Clinical trials are ongoing; no published human efficacy results yet
- Therapeutic areas
- OncologyInfectious DiseasesWomen's Health
- Modalities
- mRNA therapeuticsmRNA vaccinesLipid nanoparticle (LNP) delivery
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on RinuaGene Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RinuaGene Biotechnology.